Arbutus Biopharma
ABUS
113 hedge funds and large institutions have $119M invested in Arbutus Biopharma in 2022 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 41 increasing their positions, 37 reducing their positions, and 19 closing their positions.
83% more call options, than puts
Call options by funds: $4.81M | Put options by funds: $2.63M
11% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 37
0.26% more ownership
Funds ownership: 29.53% → 29.8% (+0.26%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5% less funds holding
Funds holding: 119 → 113 (-6)
9% less capital invested
Capital invested by funds: $131M → $119M (-$11.5M)
26% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 19
Top Buyers
| 1 |
Millennium Management
New York
|
+$5.48M |
| 2 |
TSC
Two Seas Capital
Rye,
New York
|
+$3.33M |
| 3 |
BlackRock
New York
|
+$1.83M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.19M |
| 5 |
FCM
FourWorld Capital Management
New York
|
+$648K |
Top Sellers
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
-$3.27M |
| 2 |
Goldman Sachs
New York
|
-$2.07M |
| 3 |
Prudential Financial
Newark,
New Jersey
|
-$1.08M |
| 4 |
BC
Brookfield Corp
Toronto,
Ontario, Canada
|
-$1.06M |
| 5 |
CC
Centiva Capital
New York
|
-$894K |
ABUS Hedge Fund Activity: Q2 2022 in Review
113 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q2 2022, worth a combined $119M — down 8.8% from $131M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of ABUS and 14 opened new positions — a net loss of 5 holders — while 37 trimmed existing stakes and 41 added.
The largest buyer was Millennium Management, adding an estimated $5.48M. The largest seller was Nuveen, cutting an estimated $3.27M.
- 113 institutional investors held Arbutus Biopharma (ABUS) as of Q2 2022, down from 119 in Q1 2022.
- Funds reported $119M of Arbutus Biopharma stock for Q2 2022, down 8.8% quarter-over-quarter.
- 14 funds opened new Arbutus Biopharma positions in Q2 2022 and 19 closed out, a net change of -5 holders.
- The largest Arbutus Biopharma buyer in Q2 2022 was Millennium Management, an estimated $5.48M added.
- The largest Arbutus Biopharma seller in Q2 2022 was Nuveen, an estimated $3.27M sold.
Based on aggregated 13F filings for Q2 2022.